Siraj M. Ali

48.9k citations

381 papers · 27.2k indexed · 7 hit papers · h-index 68

Molecular Biology top 0.1%
Oncology top 0.1%
Pulmonary and Respiratory Medicine top 0.1%
Cancer Research top 0.1%
Surgery top 0.5%

Co-authors: David M. Sabatini Dos D. Sarbassov David A. Guertin Robert Latek Do‐Hyung Kim Paul Tempst Hediye Erdjument‐Bromage Jeffrey S. Ross
Topics: Cancer Genomics and Diagnostics (132 papers)Lung Cancer Treatments and Mutations (108 papers)Genetic factors in colorectal cancer (41 papers)
Cited by: Oncology Cancer Research Molecular Biology
Journals: Science Cell Journal of Biological Chemistry
Partner nations: United States Italy South Korea

In The Last Decade

Siraj M. Ali

367 papers receiving 26.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

2005 5.2k citations Dos D. Sarbassov, David A. Guertin et al. Science profile →
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

2002 2.4k citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

2004 2.1k citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

2006 2.1k citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
Growing roles for the mTOR pathway

2005 1.3k citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR

2003 772 citations Dos D. Sarbassov, Siraj M. Ali et al. profile →
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

2019 441 citations Alexa B. Schrock, Ethan S. Sokol et al. profile →

Peers

Countries citing papers authored by Siraj M. Ali

Since Specialization

Citations

This map shows the geographic impact of Siraj M. Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siraj M. Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siraj M. Ali more than expected).

Fields of papers citing papers by Siraj M. Ali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siraj M. Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siraj M. Ali. The network helps show where Siraj M. Ali may publish in the future.

Co-authorship network of co-authors of Siraj M. Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Siraj M. Ali. A scholar is included among the top collaborators of Siraj M. Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siraj M. Ali. Siraj M. Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation 2019 ·Clinical Cancer Research ·Benjamin P. Brown,Yunkai Zhang,David Westover,Yingjun Yan,Huan Qiao,Vincent Huang,Zhenfang Du,Jarrod A. Smith,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Lyudmila Bazhenova,Alexa B. Schrock,Jens Meiler,Christine M. Lovly	76
2	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence 2019 ·The Oncologist ·Samuel J. Klempner,David Fabrizio,Shalmali Bane,Marcia Reinhart,Tim Peoples,Siraj M. Ali,Ethan S. Sokol,Garrett M. Frampton,Alexa B. Schrock,Rachel Anhorn,Prasanth Reddy	243
3	Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients 2019 ·Nature Communications ·Ilya G. Serebriiskii,Caitlin Connelly,Garrett M. Frampton,Justin Y. Newberg,Matthew Cooke,V. A. Miller,Siraj M. Ali,Jeffrey S. Ross,Elizabeth A. Handorf,Sanjeevani Arora,Christopher H. Lieu,Erica A. Golemis,Joshua E. Meyer	149
4	Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus 2018 ·Clinical Cancer Research ·Alexa B. Schrock,Dean C. Pavlick,Samuel J. Klempner,Jon Chung,(unknown),Allison W. Welsh,Lauren Young,B Leyland-Jones,Rodolfo Bordoni,Richard D. Carvajal,Joseph Chao,Razelle Kurzrock,Jason K. Sicklick,Jeffrey S. Ross,Philip J. Stephens,Craig Devoe,Fadi Braiteh,Siraj M. Ali,Vincent A. Miller	54
5	Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma 2018 ·The Oncologist ·Munveer S. Bhangoo,Peter D. Boasberg,(unknown),Julia A. Elvin,Siraj M. Ali,(unknown),Samuel J. Klempner	45
6	Anaplastic Lymphoma Kinase Mutation ( ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib 2018 ·Clinical Cancer Research ·Benedito A. Carneiro,Sahithi Pamarthy,Ami N. Shah,Vinay Sagar,Kenji Unno,Huiying Han,Ximing J. Yang,(unknown),Rebecca J. Nagy,Richard B. Lanman,Timothy M. Kuzel,Jeffrey S. Ross,Laurie M. Gay,Julia A. Elvin,Siraj M. Ali,Massimo Cristofanilli,Young Kwang Chae,Francis J. Giles,Sarki A. Abdulkadir	34
7	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC 2018 ·PLoS ONE ·Michael E. Goldberg,Meagan Montesion,Lauren Young,James Suh,Joel Greenbowe,Mark Kennedy,Giuseppe Giaccone,Wallace Akerley,Afshin Dowlati,Ben Creelan,J. Kevin Hicks,Paul J. Hesketh,Karen Kelly,Jonathan W. Riess,Vincent A. Miller,Philip J. Stephens,Garrett M. Frampton,Siraj M. Ali,Jeffrey P. Gregg,Lee A. Albacker	15
8	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 2018 ·Cancer ·Jeffrey S. Ross,Marwan Fakih,Siraj M. Ali,Julia A. Elvin,Alexa B. Schrock,James Suh,Jo‐Anne Vergilio,Shakti Ramkissoon,Eric A. Severson,Sugganth Daniel,David Fabrizio,Garrett M. Frampton,James Sun,Vincent A. Miller,Philip J. Stephens,Laurie M. Gay	149
9	BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy 2017 ·Pigment Cell & Melanoma Research ·Douglas B. Johnson,(unknown),Zachary R. Chalmers,Garrett M. Frampton,Siraj M. Ali,Samuel M. Rubinstein,David Fabrizio,Jeffrey S. Ross,Sohail Balasubramanian,Vincent A. Miller,Philip J. Stephens,Jeffrey A. Sosman,Christine M. Lovly	28
10	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy 2017 ·Cancer ·Siraj M. Ali,Ming Yao,Jicheng Yao,(unknown),Yu‐Wei Cheng,Alexa B. Schrock,Gung‐Wei Chirn,Hui Chen,Shuo Mu,Laurie M. Gay,Julia A. Elvin,James Suh,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross,Kai Wang	36
11	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target 2016 ·Clinical Cancer Research ·Evgeny Yakirevich,Murray B. Resnick,Shamlal Mangray,Michael B. Wheeler,Cynthia L. Jackson,Kara A. Lombardo,Jeeyun Lee,Kyoung‐Mee Kim,Anthony J. Gill,Kai Wang,Kyle Gowen,James Sun,Vincent A. Miller,Philip J. Stephens,Siraj M. Ali,Jeffrey S. Ross,Howard Safran	88
12	Significant and durable clinical benefit from trastuzumab in 2 patients with HER2‐amplified salivary gland cancer and a review of the literature 2016 ·Head & Neck ·Lauren M. Thorpe,Alexa B. Schrock,Rachel Erlich,Vincent A. Miller,James A. Knost,Nguyet Le‐Lindqwister,(unknown),Siraj M. Ali,Jane J. Liu	33
13	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences 2015 ·The Oncologist ·Kai Wang,Adrienne Johnson,Siraj M. Ali,Samuel J. Klempner,Tanios Bekaii‐Saab,Jeffrey Vacirca,Depinder Khaira,Roman Yelensky,Juliann Chmielecki,Julia A. Elvin,Doron Lipson,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross	75
14	EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib 2015 ·Cancer Discovery ·Jean‐Nicolas Gallant,Jonathan H. Sheehan,Timothy M. Shaver,Mark Bailey,Doron Lipson,Raghu Chandramohan,Monica Red Brewer,Sally J. York,Mark G. Kris,Jennifer A. Pietenpol,Marc Ladanyi,Vincent A. Miller,Siraj M. Ali,Jens Meiler,Christine M. Lovly	81
15	Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring anERBB2S310F Mutation 2015 ·Journal of the National Comprehensive Cancer Network ·Saranya Chumsri,Jodi Weidler,Siraj M. Ali,Sohail Balasubramanian,Gerald Wallweber,Lisa D. Eli,Ahmed Chenna,Weidong Huang,(unknown),(unknown),Edith A. Perez	25
16	Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes 2014 ·Cancer Discovery ·Juliann Chmielecki,Katherine E. Hutchinson,Garrett M. Frampton,Zachary R. Chalmers,Adrienne Johnson,Chanjuan Shi,Julia A. Elvin,Siraj M. Ali,Jeffrey S. Ross,Olca Baştürk,Sohail Balasubramanian,Doron Lipson,Roman Yelensky,William Pao,Vincent A. Miller,David S. Klimstra,Philip J. Stephens	126
17	Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma 2014 ·Cancer Discovery ·David Chiron,Maurizio Di Liberto,Peter Martin,Xiangao Huang,Jeff P. Sharman,Pedro Blecua,Susan Mathew,Priyanka Vijay,Ken Eng,Siraj M. Ali,Amy J. Johnson,Betty Chang,Scott Ely,Olivier Elemento,Christopher E. Mason,John P. Leonard,Selina Chen‐Kiang	204
18	Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy 2014 ·Journal of Clinical Oncology ·Siraj M. Ali,R. Katherine Alpaugh,Sean R. Downing,Philip J. Stephens,Jian Yu,Hong Wu,Jamie Buell,Vincent A. Miller,Doron Lipson,Gary A. Palmer,Jeffrey S. Ross,Massimo Cristofanilli	40
19	Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin 2014 ·The Oncologist ·Juliann Chmielecki,Jeffrey S. Ross,Kai Wang,Garrett M. Frampton,Gary A. Palmer,Siraj M. Ali,Norma Alonzo Palma,Deborah Morosini,Vincent A. Miller,Roman Yelensky,Doron Lipson,Philip J. Stephens	75
20	Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complexbreakdown → 2005 ·Science ·Dos D. Sarbassov,David A. Guertin,Siraj M. Ali,David M. Sabatini	5211

About Siraj M. Ali

Siraj M. Ali is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 381 papers that have together received 27.2k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (132 papers), Lung Cancer Treatments and Mutations (108 papers) and Genetic factors in colorectal cancer (41 papers). The work is most often cited by research in Oncology (8.8k citations), Cancer Research (4.7k citations) and Molecular Biology (15.8k citations). Siraj M. Ali has collaborated with scholars based in United States, Italy and South Korea. Frequent co-authors include David M. Sabatini, Dos D. Sarbassov, David A. Guertin, Robert Latek, Do‐Hyung Kim, Paul Tempst, Hediye Erdjument‐Bromage, Jeffrey S. Ross, Vincent A. Miller and Alexa B. Schrock. Their work appears in journals such as Science, Cell and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact